AI-generated analysis. Always verify with the original filing.
Solid Biosciences Inc. entered into a securities purchase agreement for a private placement of 14,973,257 shares of common stock at $5.61 per share and pre-funded warrants to purchase 27,807,482 shares at $5.609 per warrant, expecting gross proceeds of $240.0 million and net proceeds of $226.8 million. The net proceeds, combined with existing cash of approximately $187.9 million as of December 31, 2025, are estimated to fund operations into the first half of 2028.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), en
of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that se
Unregistered Sales of Equity Securities. The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. Based in part upo
Other Events. Based upon the Company’s current operating plan, the Company estimates that the net proceeds from the Private Placement, together with the Company
Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 10.1 Form of Securities Purchase Agreement, dated March
Material Agreement